Key Ideas

CAR-T cell therapy for large B-cell lymphoma is expanding along four fronts at once: it is being offered to older and less fit patients who were once considered poor candidates, tested earlier in the treatment course for patients with residual disease after initial therapy, compared head-to-head between products for the first time, and made more feasible for patients who live far from a treating center through remote monitoring technology.

Who Is a Candidate: Real-World Data on Age and Fitness

A real-world evidence analysis of CAR-T outcomes in large B-cell lymphoma found that older age did not significantly affect efficacy or survival. That finding matters because CAR-T cell therapy does carry real, acute toxicity, but most patients, including older patients, recover well afterward: health-related quality of life measures after CAR-T cell therapy in transplant-ineligible patients have been comparable to what is seen in transplant-eligible patients receiving the same therapy. Age alone should not be a barrier to considering CAR-T cell therapy.

Dedicated Trials for Transplant-Ineligible Patients

Roughly half of patients with relapsed or refractory large B-cell lymphoma are considered ineligible for autologous stem cell transplantation in the second-line setting, a population not directly studied in the pivotal randomized trials that established CAR-T cell therapy as second-line treatment. Dedicated trials have since filled that gap: the ALYCANTE study evaluated axicabtagene ciloleucel specifically in transplant-ineligible patients, and the PILOT study evaluated lisocabtagene maraleucel in the same population, both showing encouraging efficacy in patients who would previously have been steered toward less intensive salvage therapy alone.

What Products Are Available and How They Compare

Two CAR-T products are currently approved for second line treatment of large B-cell lymphoma, either primary refractory or relapsed within 12 months. Axicabtagene ciloleucel (axi-cel) has a shorter manufacturing time and a slightly higher manufacturing success rate compared with lisocabtagene maraleucel (liso-cel). There has not been a prospective head-to-head trial comparing the two directly, and available real-world evidence comparing them have shown variable results, so no strong conclusion about relative efficacy can be drawn yet. For patients with more aggressive disease kinetics, axi-cel may be preferred. In contrast, for those patients who are older, frailer, or can wait longer for a product with a differentiated toxicity profile, liso-cel is often preferred. Tisagenlecleucel is also a viable CAR-T option in the third line and beyond. Notably, a new head-to-head trial, PiNACLE-H2H, is now underway, randomizing patients to rondecabtagene autoleucel, an autologous CD19/CD20 dual-targeting CAR-T cell product, against investigator's choice of axicabtagene ciloleucel or lisocabtagene maraleucel in the second-line setting. This is the first genuine head-to-head comparison between CAR-T products in this disease, and its results should meaningfully clarify how these options stack up against one another.

When to Treat: Moving CAR-T Cell Therapy Earlier Based on MRD Status

CAR-T cell therapy is currently used after relapse, but a recurring question is whether it should be used earlier in the cancer journey, before a patient has accumulated more chemotherapy exposure. This matters because more chemotherapy tends to leave the patient’s T cells more exhausted; collecting T-cells for T-cell based therapies earlier allows the use of more naive and early memory T-cell phenotypes, which are associated with more durable responses after infusion. Additionally, measurable residual disease status at the end of frontline induction appears predictive of outcomes even in patients who otherwise look like they achieved a complete response by imaging, which raises the question of how to use that information to guide earlier intervention. The ALPHA3 trial is addressing this directly: it is a phase 2 randomized trial testing early CAR-T cell consolidation, using the allogeneic, off-the-shelf CD19-directed CAR-T product cemacabtagene ansegedleucel, against routine imaging-based follow-up in patients who are measurable residual disease-positive after frontline induction for large B-cell lymphoma. Interim results have shown a numerically higher rate of measurable residual disease clearance favoring cemacabtagene ansegedleucel over observation.

Where to Deliver CAR-T: The Logistics Problem

Even when a patient is a candidate for CAR-T cell therapy and a product is chosen, delivering it is genuinely complicated. Mapping the fully accredited cellular therapy centers across a state illustrates the problem well: many patients simply live too far from a qualified center for the distance to be practical, particularly for the close monitoring period after infusion. One strategy under investigation is remote digital monitoring. Duke University has investigated a novel combinatorial digital monitoring strategy combining a wearable, high-frequency temperature-monitoring patch (TempTraq) with an additional mobile health-supported remote photoplethysmography application (VitalTraq) that measures blood pressure, heart rate, and respiratory rate in a contact-free manner. In a clinical trial, when this digital monitoring platform was tested against standard-of-care monitoring, the study found a meaningful lead time, on the order of a full day, in detecting cytokine release syndrome, largely due to catching brief temperature spikes that standard monitoring would otherwise miss. Approaches like this could offer a relatively low-cost way to extend the effective treatment radius of a CAR-T cell program without requiring patients to relocate near the treating center for weeks at a time. Separately, an investigational, in vivo-generated CD22-directed CAR-T cell therapy (UB-VV400), delivered as a single infusion without the delay of ex vivo manufacturing, has recently received FDA clearance to begin human testing, and represents another potential path toward making cellular therapy delivery less logistically burdensome.

For Patients

If considering CAR-T cell therapy for large B-cell lymphoma, age or distance from a major treatment center should not automatically rule this out as an option. It is worth asking directly about eligibility for CAR-T cell therapy even if ineligible for stem cell transplantation, and about whether the treating center has remote monitoring or other strategies in place to reduce the burden of travel and prolonged stays near the treatment site.

Key Takeaways

  • Real-world data show that age does not significantly affect CAR-T cell therapy efficacy or survival in large B-cell lymphoma, including in patients 75 and older.

  • Dedicated trials, ALYCANTE for axicabtagene ciloleucel and PILOT for lisocabtagene maraleucel, have shown encouraging results specifically in transplant-ineligible patients.

  • The PiNACLE-H2H trial is the first prospective head-to-head comparison between CAR-T products for second-line treatment of large B cell lymphoma, testing rondecabtagene autoleucel against investigator choice of axicabtagene ciloleucel or lisocabtagene maraleucel.

  • The ALPHA3 trial is testing whether early CAR-T cell consolidation to eradicate measurable residual disease after frontline therapy improves outcomes compared with routine observation.

  • Remote digital monitoring technology and in vivo-generated CAR-T cell approaches are both being explored as ways to reduce the logistical burden of delivering CAR-T cell therapy to patients who live far from treatment centers.

References

  1. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine. 2022.

  2. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM). The Lancet. 2022.

  3. Houot R, et al. Axicabtagene ciloleucel as second-line therapy in large B-cell lymphoma ineligible for autologous stem cell transplantation (ALYCANTE). Nature Medicine. 2024.

  4. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT). The Lancet Oncology. 2022.

  5. Lyell Immunopharma. PiNACLE-H2H: a phase 3 head-to-head trial of rondecabtagene autoleucel versus investigator's choice of lisocabtagene maraleucel or axicabtagene ciloleucel in second-line large B-cell lymphoma. Presented data.

  6. Allogene Therapeutics. ALPHA3: a phase 2 randomized trial of cemacabtagene ansegedleucel consolidation for measurable residual disease-positive large B-cell lymphoma after frontline therapy. Presented data.